nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—CA2—esophageal cancer	0.409	0.761	CbGaD
Celecoxib—PTGS2—esophageal cancer	0.128	0.239	CbGaD
Celecoxib—ABCC4—Methotrexate—esophageal cancer	0.0454	0.313	CbGbCtD
Celecoxib—PTGS2—Cisplatin—esophageal cancer	0.0411	0.283	CbGbCtD
Celecoxib—CYP2C9—Capecitabine—esophageal cancer	0.0277	0.191	CbGbCtD
Celecoxib—ALB—Methotrexate—esophageal cancer	0.0168	0.116	CbGbCtD
Celecoxib—CYP2C9—Cisplatin—esophageal cancer	0.014	0.0963	CbGbCtD
Celecoxib—CA6—exocrine gland—esophageal cancer	0.00423	0.101	CbGeAlD
Celecoxib—MAPK14—neck—esophageal cancer	0.00239	0.0571	CbGeAlD
Celecoxib—PDPK1—digestive system—esophageal cancer	0.00231	0.0553	CbGeAlD
Celecoxib—PDPK1—lung—esophageal cancer	0.00193	0.0462	CbGeAlD
Celecoxib—MAPK14—epithelium—esophageal cancer	0.00163	0.0389	CbGeAlD
Celecoxib—MAPK14—bronchus—esophageal cancer	0.0016	0.0383	CbGeAlD
Celecoxib—MAPK14—smooth muscle tissue—esophageal cancer	0.00157	0.0375	CbGeAlD
Celecoxib—CA2—exocrine gland—esophageal cancer	0.00146	0.0348	CbGeAlD
Celecoxib—PDPK1—lymph node—esophageal cancer	0.00132	0.0316	CbGeAlD
Celecoxib—CA9—digestive system—esophageal cancer	0.00127	0.0303	CbGeAlD
Celecoxib—MAPK14—digestive system—esophageal cancer	0.00124	0.0296	CbGeAlD
Celecoxib—Sulfaphenazole—CYP2A6—esophageal cancer	0.00121	0.569	CrCbGaD
Celecoxib—CA4—neck—esophageal cancer	0.00112	0.0268	CbGeAlD
Celecoxib—CA12—trachea—esophageal cancer	0.00109	0.0261	CbGeAlD
Celecoxib—MAPK14—lung—esophageal cancer	0.00103	0.0247	CbGeAlD
Celecoxib—CA12—digestive system—esophageal cancer	0.000939	0.0224	CbGeAlD
Celecoxib—CA2—neck—esophageal cancer	0.000932	0.0223	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—esophageal cancer	0.000921	0.432	CrCbGaD
Celecoxib—ABCC4—bronchus—esophageal cancer	0.000819	0.0196	CbGeAlD
Celecoxib—CA12—lung—esophageal cancer	0.000784	0.0187	CbGeAlD
Celecoxib—MAPK14—lymph node—esophageal cancer	0.000707	0.0169	CbGeAlD
Celecoxib—CA5B—lung—esophageal cancer	0.000704	0.0168	CbGeAlD
Celecoxib—CA4—trachea—esophageal cancer	0.000676	0.0162	CbGeAlD
Celecoxib—CA2—epithelium—esophageal cancer	0.000634	0.0151	CbGeAlD
Celecoxib—ABCC4—digestive system—esophageal cancer	0.000633	0.0151	CbGeAlD
Celecoxib—CA2—bronchus—esophageal cancer	0.000624	0.0149	CbGeAlD
Celecoxib—ORM1—lung—esophageal cancer	0.000622	0.0149	CbGeAlD
Celecoxib—CA2—smooth muscle tissue—esophageal cancer	0.000611	0.0146	CbGeAlD
Celecoxib—CA4—digestive system—esophageal cancer	0.000582	0.0139	CbGeAlD
Celecoxib—CA2—trachea—esophageal cancer	0.000561	0.0134	CbGeAlD
Celecoxib—ABCC4—lung—esophageal cancer	0.000528	0.0126	CbGeAlD
Celecoxib—CA4—lung—esophageal cancer	0.000486	0.0116	CbGeAlD
Celecoxib—CA2—digestive system—esophageal cancer	0.000482	0.0115	CbGeAlD
Celecoxib—CA5B—lymph node—esophageal cancer	0.000481	0.0115	CbGeAlD
Celecoxib—PTGS2—epithelium—esophageal cancer	0.000468	0.0112	CbGeAlD
Celecoxib—PTGS2—bronchus—esophageal cancer	0.000461	0.011	CbGeAlD
Celecoxib—PTGS2—smooth muscle tissue—esophageal cancer	0.000451	0.0108	CbGeAlD
Celecoxib—ORM1—lymph node—esophageal cancer	0.000426	0.0102	CbGeAlD
Celecoxib—PTGS2—trachea—esophageal cancer	0.000414	0.00989	CbGeAlD
Celecoxib—CYP2C9—digestive system—esophageal cancer	0.000408	0.00975	CbGeAlD
Celecoxib—CA2—lung—esophageal cancer	0.000403	0.00962	CbGeAlD
Celecoxib—ALB—lymph node—esophageal cancer	0.000373	0.00892	CbGeAlD
Celecoxib—ABCC4—lymph node—esophageal cancer	0.000361	0.00863	CbGeAlD
Celecoxib—PTGS2—digestive system—esophageal cancer	0.000356	0.00851	CbGeAlD
Celecoxib—CA4—lymph node—esophageal cancer	0.000332	0.00794	CbGeAlD
Celecoxib—CYP3A4—digestive system—esophageal cancer	0.000311	0.00743	CbGeAlD
Celecoxib—CYP2D6—digestive system—esophageal cancer	0.000306	0.00731	CbGeAlD
Celecoxib—PTGS2—lung—esophageal cancer	0.000297	0.0071	CbGeAlD
Celecoxib—CA2—lymph node—esophageal cancer	0.000275	0.00658	CbGeAlD
Celecoxib—Skin exfoliation—Methotrexate—esophageal cancer	0.000265	0.00259	CcSEcCtD
Celecoxib—Vaginal infection—Methotrexate—esophageal cancer	0.000262	0.00256	CcSEcCtD
Celecoxib—Face oedema—Capecitabine—esophageal cancer	0.000261	0.00255	CcSEcCtD
Celecoxib—Aplastic anaemia—Methotrexate—esophageal cancer	0.000261	0.00255	CcSEcCtD
Celecoxib—Ataxia—Capecitabine—esophageal cancer	0.000255	0.00249	CcSEcCtD
Celecoxib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000254	0.00248	CcSEcCtD
Celecoxib—Bladder pain—Methotrexate—esophageal cancer	0.000251	0.00245	CcSEcCtD
Celecoxib—Ecchymosis—Methotrexate—esophageal cancer	0.000251	0.00245	CcSEcCtD
Celecoxib—Mouth ulceration—Methotrexate—esophageal cancer	0.000251	0.00245	CcSEcCtD
Celecoxib—Neoplasm—Methotrexate—esophageal cancer	0.000251	0.00245	CcSEcCtD
Celecoxib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000251	0.00245	CcSEcCtD
Celecoxib—Liver function test abnormal—Capecitabine—esophageal cancer	0.00025	0.00244	CcSEcCtD
Celecoxib—Connective tissue disorder—Cisplatin—esophageal cancer	0.00025	0.00244	CcSEcCtD
Celecoxib—Urethral disorder—Cisplatin—esophageal cancer	0.000249	0.00243	CcSEcCtD
Celecoxib—Dry skin—Capecitabine—esophageal cancer	0.000248	0.00243	CcSEcCtD
Celecoxib—Abdominal pain upper—Capecitabine—esophageal cancer	0.000247	0.00242	CcSEcCtD
Celecoxib—Hypokalaemia—Capecitabine—esophageal cancer	0.000246	0.00241	CcSEcCtD
Celecoxib—Breast disorder—Capecitabine—esophageal cancer	0.000245	0.00239	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000244	0.00238	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000244	0.00238	CcSEcCtD
Celecoxib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000242	0.00237	CcSEcCtD
Celecoxib—Sepsis—Methotrexate—esophageal cancer	0.000241	0.00236	CcSEcCtD
Celecoxib—Gastritis—Capecitabine—esophageal cancer	0.00024	0.00234	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000239	0.00233	CcSEcCtD
Celecoxib—Eye disorder—Cisplatin—esophageal cancer	0.000237	0.00232	CcSEcCtD
Celecoxib—Tinnitus—Cisplatin—esophageal cancer	0.000237	0.00232	CcSEcCtD
Celecoxib—Cardiac disorder—Cisplatin—esophageal cancer	0.000236	0.00231	CcSEcCtD
Celecoxib—Flushing—Cisplatin—esophageal cancer	0.000236	0.00231	CcSEcCtD
Celecoxib—Dysphagia—Capecitabine—esophageal cancer	0.000234	0.00229	CcSEcCtD
Celecoxib—Thrombophlebitis—Methotrexate—esophageal cancer	0.000233	0.00228	CcSEcCtD
Celecoxib—Diabetes mellitus—Methotrexate—esophageal cancer	0.000232	0.00227	CcSEcCtD
Celecoxib—Bronchospasm—Capecitabine—esophageal cancer	0.00023	0.00225	CcSEcCtD
Celecoxib—Photosensitivity—Methotrexate—esophageal cancer	0.000229	0.00224	CcSEcCtD
Celecoxib—Immune system disorder—Cisplatin—esophageal cancer	0.000229	0.00224	CcSEcCtD
Celecoxib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000229	0.00224	CcSEcCtD
Celecoxib—Sweating increased—Capecitabine—esophageal cancer	0.000228	0.00223	CcSEcCtD
Celecoxib—Angina pectoris—Capecitabine—esophageal cancer	0.000228	0.00223	CcSEcCtD
Celecoxib—Arrhythmia—Cisplatin—esophageal cancer	0.000227	0.00222	CcSEcCtD
Celecoxib—Bronchitis—Capecitabine—esophageal cancer	0.000225	0.0022	CcSEcCtD
Celecoxib—Alopecia—Cisplatin—esophageal cancer	0.000224	0.00219	CcSEcCtD
Celecoxib—Hepatic failure—Methotrexate—esophageal cancer	0.000224	0.00219	CcSEcCtD
Celecoxib—Pancytopenia—Capecitabine—esophageal cancer	0.000222	0.00217	CcSEcCtD
Celecoxib—Dysuria—Capecitabine—esophageal cancer	0.000219	0.00214	CcSEcCtD
Celecoxib—Renal failure acute—Methotrexate—esophageal cancer	0.000218	0.00213	CcSEcCtD
Celecoxib—Flatulence—Cisplatin—esophageal cancer	0.000218	0.00213	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000217	0.00213	CcSEcCtD
Celecoxib—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000214	0.00209	CcSEcCtD
Celecoxib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000214	0.00209	CcSEcCtD
Celecoxib—Weight increased—Capecitabine—esophageal cancer	0.000213	0.00208	CcSEcCtD
Celecoxib—Muscle spasms—Cisplatin—esophageal cancer	0.000213	0.00208	CcSEcCtD
Celecoxib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000211	0.00206	CcSEcCtD
Celecoxib—Pneumonia—Capecitabine—esophageal cancer	0.00021	0.00205	CcSEcCtD
Celecoxib—Infestation NOS—Capecitabine—esophageal cancer	0.000209	0.00204	CcSEcCtD
Celecoxib—Infestation—Capecitabine—esophageal cancer	0.000209	0.00204	CcSEcCtD
Celecoxib—Vision blurred—Cisplatin—esophageal cancer	0.000208	0.00204	CcSEcCtD
Celecoxib—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000208	0.00204	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000207	0.00202	CcSEcCtD
Celecoxib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000206	0.00201	CcSEcCtD
Celecoxib—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000206	0.00201	CcSEcCtD
Celecoxib—Myocardial infarction—Capecitabine—esophageal cancer	0.000204	0.002	CcSEcCtD
Celecoxib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000204	0.002	CcSEcCtD
Celecoxib—Anaemia—Cisplatin—esophageal cancer	0.000204	0.002	CcSEcCtD
Celecoxib—PTGS2—lymph node—esophageal cancer	0.000203	0.00486	CbGeAlD
Celecoxib—Stomatitis—Capecitabine—esophageal cancer	0.000203	0.00199	CcSEcCtD
Celecoxib—Jaundice—Capecitabine—esophageal cancer	0.000203	0.00199	CcSEcCtD
Celecoxib—Urinary tract infection—Capecitabine—esophageal cancer	0.000203	0.00198	CcSEcCtD
Celecoxib—Conjunctivitis—Capecitabine—esophageal cancer	0.000203	0.00198	CcSEcCtD
Celecoxib—Osteoarthritis—Methotrexate—esophageal cancer	0.000202	0.00197	CcSEcCtD
Celecoxib—Haematuria—Capecitabine—esophageal cancer	0.000199	0.00194	CcSEcCtD
Celecoxib—Leukopenia—Cisplatin—esophageal cancer	0.000198	0.00194	CcSEcCtD
Celecoxib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000197	0.00193	CcSEcCtD
Celecoxib—Epistaxis—Capecitabine—esophageal cancer	0.000197	0.00192	CcSEcCtD
Celecoxib—Agranulocytosis—Capecitabine—esophageal cancer	0.000195	0.0019	CcSEcCtD
Celecoxib—Ataxia—Methotrexate—esophageal cancer	0.000189	0.00185	CcSEcCtD
Celecoxib—Myalgia—Cisplatin—esophageal cancer	0.000188	0.00184	CcSEcCtD
Celecoxib—Haemoglobin—Capecitabine—esophageal cancer	0.000188	0.00184	CcSEcCtD
Celecoxib—Rhinitis—Capecitabine—esophageal cancer	0.000188	0.00184	CcSEcCtD
Celecoxib—Anxiety—Cisplatin—esophageal cancer	0.000188	0.00183	CcSEcCtD
Celecoxib—Haemorrhage—Capecitabine—esophageal cancer	0.000187	0.00183	CcSEcCtD
Celecoxib—Hepatitis—Capecitabine—esophageal cancer	0.000187	0.00183	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000187	0.00183	CcSEcCtD
Celecoxib—Hypoaesthesia—Capecitabine—esophageal cancer	0.000186	0.00182	CcSEcCtD
Celecoxib—Liver function test abnormal—Methotrexate—esophageal cancer	0.000186	0.00182	CcSEcCtD
Celecoxib—Pharyngitis—Capecitabine—esophageal cancer	0.000186	0.00182	CcSEcCtD
Celecoxib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000185	0.00181	CcSEcCtD
Celecoxib—Oedema peripheral—Capecitabine—esophageal cancer	0.000184	0.0018	CcSEcCtD
Celecoxib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000184	0.0018	CcSEcCtD
Celecoxib—Urethral disorder—Capecitabine—esophageal cancer	0.000184	0.00179	CcSEcCtD
Celecoxib—Breast disorder—Methotrexate—esophageal cancer	0.000182	0.00178	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000181	0.00177	CcSEcCtD
Celecoxib—Anaphylactic shock—Cisplatin—esophageal cancer	0.00018	0.00176	CcSEcCtD
Celecoxib—Oedema—Cisplatin—esophageal cancer	0.00018	0.00176	CcSEcCtD
Celecoxib—Infection—Cisplatin—esophageal cancer	0.000179	0.00175	CcSEcCtD
Celecoxib—Erythema multiforme—Capecitabine—esophageal cancer	0.000177	0.00173	CcSEcCtD
Celecoxib—Nervous system disorder—Cisplatin—esophageal cancer	0.000177	0.00173	CcSEcCtD
Celecoxib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000177	0.00173	CcSEcCtD
Celecoxib—Tachycardia—Cisplatin—esophageal cancer	0.000176	0.00172	CcSEcCtD
Celecoxib—Skin disorder—Cisplatin—esophageal cancer	0.000175	0.00171	CcSEcCtD
Celecoxib—Eye disorder—Capecitabine—esophageal cancer	0.000175	0.00171	CcSEcCtD
Celecoxib—Tinnitus—Capecitabine—esophageal cancer	0.000175	0.00171	CcSEcCtD
Celecoxib—Hyperhidrosis—Cisplatin—esophageal cancer	0.000174	0.00171	CcSEcCtD
Celecoxib—Flushing—Capecitabine—esophageal cancer	0.000174	0.0017	CcSEcCtD
Celecoxib—Cardiac disorder—Capecitabine—esophageal cancer	0.000174	0.0017	CcSEcCtD
Celecoxib—Eosinophilia—Methotrexate—esophageal cancer	0.000172	0.00169	CcSEcCtD
Celecoxib—Anorexia—Cisplatin—esophageal cancer	0.000172	0.00168	CcSEcCtD
Celecoxib—Pancreatitis—Methotrexate—esophageal cancer	0.000171	0.00167	CcSEcCtD
Celecoxib—Angiopathy—Capecitabine—esophageal cancer	0.00017	0.00166	CcSEcCtD
Celecoxib—Immune system disorder—Capecitabine—esophageal cancer	0.000169	0.00165	CcSEcCtD
Celecoxib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000169	0.00165	CcSEcCtD
Celecoxib—Arrhythmia—Capecitabine—esophageal cancer	0.000167	0.00164	CcSEcCtD
Celecoxib—Alopecia—Capecitabine—esophageal cancer	0.000165	0.00162	CcSEcCtD
Celecoxib—Pancytopenia—Methotrexate—esophageal cancer	0.000165	0.00162	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000164	0.00161	CcSEcCtD
Celecoxib—Mental disorder—Capecitabine—esophageal cancer	0.000164	0.0016	CcSEcCtD
Celecoxib—Dysuria—Methotrexate—esophageal cancer	0.000163	0.00159	CcSEcCtD
Celecoxib—Paraesthesia—Cisplatin—esophageal cancer	0.000162	0.00158	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000162	0.00158	CcSEcCtD
Celecoxib—Dyspnoea—Cisplatin—esophageal cancer	0.000161	0.00157	CcSEcCtD
Celecoxib—Flatulence—Capecitabine—esophageal cancer	0.000161	0.00157	CcSEcCtD
Celecoxib—Dysgeusia—Capecitabine—esophageal cancer	0.00016	0.00156	CcSEcCtD
Celecoxib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000159	0.00155	CcSEcCtD
Celecoxib—Back pain—Capecitabine—esophageal cancer	0.000158	0.00154	CcSEcCtD
Celecoxib—Decreased appetite—Cisplatin—esophageal cancer	0.000157	0.00153	CcSEcCtD
Celecoxib—Muscle spasms—Capecitabine—esophageal cancer	0.000157	0.00153	CcSEcCtD
Celecoxib—Pneumonia—Methotrexate—esophageal cancer	0.000156	0.00153	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000156	0.00152	CcSEcCtD
Celecoxib—Infestation NOS—Methotrexate—esophageal cancer	0.000155	0.00152	CcSEcCtD
Celecoxib—Infestation—Methotrexate—esophageal cancer	0.000155	0.00152	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000154	0.00151	CcSEcCtD
Celecoxib—Vision blurred—Capecitabine—esophageal cancer	0.000154	0.0015	CcSEcCtD
Celecoxib—Stomatitis—Methotrexate—esophageal cancer	0.000151	0.00148	CcSEcCtD
Celecoxib—Conjunctivitis—Methotrexate—esophageal cancer	0.000151	0.00148	CcSEcCtD
Celecoxib—Anaemia—Capecitabine—esophageal cancer	0.000151	0.00147	CcSEcCtD
Celecoxib—Feeling abnormal—Cisplatin—esophageal cancer	0.000149	0.00145	CcSEcCtD
Celecoxib—Haematuria—Methotrexate—esophageal cancer	0.000148	0.00145	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000147	0.00144	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—esophageal cancer	0.000146	0.00143	CcSEcCtD
Celecoxib—Vertigo—Capecitabine—esophageal cancer	0.000146	0.00143	CcSEcCtD
Celecoxib—Syncope—Capecitabine—esophageal cancer	0.000146	0.00143	CcSEcCtD
Celecoxib—Leukopenia—Capecitabine—esophageal cancer	0.000146	0.00143	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—esophageal cancer	0.000145	0.00142	CcSEcCtD
Celecoxib—Palpitations—Capecitabine—esophageal cancer	0.000144	0.00141	CcSEcCtD
Celecoxib—Loss of consciousness—Capecitabine—esophageal cancer	0.000143	0.0014	CcSEcCtD
Celecoxib—Body temperature increased—Cisplatin—esophageal cancer	0.000143	0.00139	CcSEcCtD
Celecoxib—Cough—Capecitabine—esophageal cancer	0.000142	0.00139	CcSEcCtD
Celecoxib—Hypertension—Capecitabine—esophageal cancer	0.000141	0.00138	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—esophageal cancer	0.00014	0.00137	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—esophageal cancer	0.000139	0.00136	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—esophageal cancer	0.000139	0.00136	CcSEcCtD
Celecoxib—Arthralgia—Capecitabine—esophageal cancer	0.000139	0.00136	CcSEcCtD
Celecoxib—Myalgia—Capecitabine—esophageal cancer	0.000139	0.00136	CcSEcCtD
Celecoxib—Chest pain—Capecitabine—esophageal cancer	0.000139	0.00136	CcSEcCtD
Celecoxib—Pharyngitis—Methotrexate—esophageal cancer	0.000138	0.00135	CcSEcCtD
Celecoxib—Anxiety—Capecitabine—esophageal cancer	0.000138	0.00135	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000138	0.00135	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000138	0.00135	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—esophageal cancer	0.000137	0.00134	CcSEcCtD
Celecoxib—Dry mouth—Capecitabine—esophageal cancer	0.000136	0.00133	CcSEcCtD
Celecoxib—Confusional state—Capecitabine—esophageal cancer	0.000134	0.00131	CcSEcCtD
Celecoxib—Oedema—Capecitabine—esophageal cancer	0.000133	0.0013	CcSEcCtD
Celecoxib—Hypersensitivity—Cisplatin—esophageal cancer	0.000133	0.0013	CcSEcCtD
Celecoxib—Infection—Capecitabine—esophageal cancer	0.000132	0.00129	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—esophageal cancer	0.000132	0.00129	CcSEcCtD
Celecoxib—Shock—Capecitabine—esophageal cancer	0.000131	0.00128	CcSEcCtD
Celecoxib—Nervous system disorder—Capecitabine—esophageal cancer	0.00013	0.00128	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—esophageal cancer	0.00013	0.00127	CcSEcCtD
Celecoxib—Thrombocytopenia—Capecitabine—esophageal cancer	0.00013	0.00127	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—esophageal cancer	0.00013	0.00127	CcSEcCtD
Celecoxib—Tachycardia—Capecitabine—esophageal cancer	0.00013	0.00127	CcSEcCtD
Celecoxib—Asthenia—Cisplatin—esophageal cancer	0.000129	0.00127	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—esophageal cancer	0.000129	0.00126	CcSEcCtD
Celecoxib—Skin disorder—Capecitabine—esophageal cancer	0.000129	0.00126	CcSEcCtD
Celecoxib—Hyperhidrosis—Capecitabine—esophageal cancer	0.000129	0.00126	CcSEcCtD
Celecoxib—Anorexia—Capecitabine—esophageal cancer	0.000127	0.00124	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—esophageal cancer	0.000126	0.00124	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—esophageal cancer	0.000126	0.00123	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000126	0.00123	CcSEcCtD
Celecoxib—Diarrhoea—Cisplatin—esophageal cancer	0.000123	0.00121	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—esophageal cancer	0.000123	0.0012	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—esophageal cancer	0.000122	0.00119	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000121	0.00119	CcSEcCtD
Celecoxib—Insomnia—Capecitabine—esophageal cancer	0.00012	0.00118	CcSEcCtD
Celecoxib—Paraesthesia—Capecitabine—esophageal cancer	0.000119	0.00117	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—esophageal cancer	0.000119	0.00116	CcSEcCtD
Celecoxib—Dyspnoea—Capecitabine—esophageal cancer	0.000119	0.00116	CcSEcCtD
Celecoxib—Back pain—Methotrexate—esophageal cancer	0.000117	0.00115	CcSEcCtD
Celecoxib—Dyspepsia—Capecitabine—esophageal cancer	0.000117	0.00114	CcSEcCtD
Celecoxib—Decreased appetite—Capecitabine—esophageal cancer	0.000116	0.00113	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000115	0.00112	CcSEcCtD
Celecoxib—Vomiting—Cisplatin—esophageal cancer	0.000115	0.00112	CcSEcCtD
Celecoxib—Fatigue—Capecitabine—esophageal cancer	0.000115	0.00112	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—esophageal cancer	0.000114	0.00112	CcSEcCtD
Celecoxib—Rash—Cisplatin—esophageal cancer	0.000114	0.00111	CcSEcCtD
Celecoxib—Constipation—Capecitabine—esophageal cancer	0.000114	0.00111	CcSEcCtD
Celecoxib—Dermatitis—Cisplatin—esophageal cancer	0.000114	0.00111	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—esophageal cancer	0.000112	0.0011	CcSEcCtD
Celecoxib—Feeling abnormal—Capecitabine—esophageal cancer	0.00011	0.00107	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—esophageal cancer	0.000109	0.00107	CcSEcCtD
Celecoxib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000109	0.00106	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—esophageal cancer	0.000109	0.00106	CcSEcCtD
Celecoxib—Nausea—Cisplatin—esophageal cancer	0.000107	0.00105	CcSEcCtD
Celecoxib—Cough—Methotrexate—esophageal cancer	0.000106	0.00104	CcSEcCtD
Celecoxib—Urticaria—Capecitabine—esophageal cancer	0.000106	0.00103	CcSEcCtD
Celecoxib—Abdominal pain—Capecitabine—esophageal cancer	0.000105	0.00103	CcSEcCtD
Celecoxib—Body temperature increased—Capecitabine—esophageal cancer	0.000105	0.00103	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—esophageal cancer	0.000103	0.00101	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—esophageal cancer	0.000103	0.00101	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—esophageal cancer	0.000103	0.00101	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000103	0.001	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—esophageal cancer	9.99e-05	0.000976	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—esophageal cancer	9.9e-05	0.000968	CcSEcCtD
Celecoxib—Infection—Methotrexate—esophageal cancer	9.84e-05	0.000962	CcSEcCtD
Celecoxib—Hypersensitivity—Capecitabine—esophageal cancer	9.8e-05	0.000958	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—esophageal cancer	9.71e-05	0.00095	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—esophageal cancer	9.7e-05	0.000948	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—esophageal cancer	9.62e-05	0.000941	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—esophageal cancer	9.57e-05	0.000936	CcSEcCtD
Celecoxib—Asthenia—Capecitabine—esophageal cancer	9.55e-05	0.000933	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—esophageal cancer	9.44e-05	0.000923	CcSEcCtD
Celecoxib—Pruritus—Capecitabine—esophageal cancer	9.41e-05	0.00092	CcSEcCtD
Celecoxib—Diarrhoea—Capecitabine—esophageal cancer	9.1e-05	0.00089	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.02e-05	0.000882	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—esophageal cancer	8.96e-05	0.000876	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—esophageal cancer	8.89e-05	0.000869	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—esophageal cancer	8.83e-05	0.000863	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—esophageal cancer	8.8e-05	0.000861	CcSEcCtD
Celecoxib—Dizziness—Capecitabine—esophageal cancer	8.8e-05	0.00086	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—esophageal cancer	8.72e-05	0.000852	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—esophageal cancer	8.61e-05	0.000842	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.55e-05	0.000836	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—esophageal cancer	8.54e-05	0.000835	CcSEcCtD
Celecoxib—Vomiting—Capecitabine—esophageal cancer	8.46e-05	0.000827	CcSEcCtD
Celecoxib—Rash—Capecitabine—esophageal cancer	8.39e-05	0.00082	CcSEcCtD
Celecoxib—Dermatitis—Capecitabine—esophageal cancer	8.38e-05	0.000819	CcSEcCtD
Celecoxib—Headache—Capecitabine—esophageal cancer	8.33e-05	0.000815	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—esophageal cancer	8.16e-05	0.000798	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—esophageal cancer	8.1e-05	0.000792	CcSEcCtD
Celecoxib—Nausea—Capecitabine—esophageal cancer	7.9e-05	0.000773	CcSEcCtD
Celecoxib—Urticaria—Methotrexate—esophageal cancer	7.87e-05	0.000769	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—esophageal cancer	7.83e-05	0.000765	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—esophageal cancer	7.83e-05	0.000765	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—esophageal cancer	7.3e-05	0.000713	CcSEcCtD
Celecoxib—Asthenia—Methotrexate—esophageal cancer	7.11e-05	0.000695	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—esophageal cancer	7.01e-05	0.000685	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—esophageal cancer	6.78e-05	0.000663	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—esophageal cancer	6.55e-05	0.00064	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—esophageal cancer	6.3e-05	0.000616	CcSEcCtD
Celecoxib—Rash—Methotrexate—esophageal cancer	6.24e-05	0.000611	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—esophageal cancer	6.24e-05	0.00061	CcSEcCtD
Celecoxib—Headache—Methotrexate—esophageal cancer	6.2e-05	0.000607	CcSEcCtD
Celecoxib—Nausea—Methotrexate—esophageal cancer	5.88e-05	0.000575	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—SST—esophageal cancer	9.83e-06	5.72e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—B2M—esophageal cancer	9.81e-06	5.7e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EP300—esophageal cancer	9.78e-06	5.69e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TYMP—esophageal cancer	9.7e-06	5.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—EP300—esophageal cancer	9.69e-06	5.63e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTGS2—esophageal cancer	9.69e-06	5.63e-05	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	9.66e-06	5.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH3—esophageal cancer	9.58e-06	5.57e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—GHRL—esophageal cancer	9.58e-06	5.57e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—CREBBP—esophageal cancer	9.56e-06	5.56e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ADH7—esophageal cancer	9.55e-06	5.55e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PLCE1—esophageal cancer	9.55e-06	5.55e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	9.52e-06	5.54e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CDKN1A—esophageal cancer	9.49e-06	5.52e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PLCE1—esophageal cancer	9.47e-06	5.51e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ADH7—esophageal cancer	9.47e-06	5.51e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP26A1—esophageal cancer	9.43e-06	5.48e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GNG7—esophageal cancer	9.43e-06	5.48e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FBXW7—esophageal cancer	9.43e-06	5.48e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ENO1—esophageal cancer	9.4e-06	5.47e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.36e-06	5.44e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTGS2—esophageal cancer	9.29e-06	5.4e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CREBBP—esophageal cancer	9.28e-06	5.4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PSME2—esophageal cancer	9.27e-06	5.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PSME1—esophageal cancer	9.27e-06	5.39e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ALOX15—esophageal cancer	9.19e-06	5.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CDKN1A—esophageal cancer	9.17e-06	5.33e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—EGFR—esophageal cancer	9.12e-06	5.3e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EP300—esophageal cancer	9.03e-06	5.25e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CALR—esophageal cancer	8.89e-06	5.17e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PIK3CA—esophageal cancer	8.87e-06	5.16e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ALDH2—esophageal cancer	8.84e-06	5.14e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTO1—esophageal cancer	8.77e-06	5.1e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TPI1—esophageal cancer	8.77e-06	5.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TLR4—esophageal cancer	8.73e-06	5.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EP300—esophageal cancer	8.72e-06	5.07e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.72e-06	5.07e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—PIK3CA—esophageal cancer	8.64e-06	5.03e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PIK3CA—esophageal cancer	8.64e-06	5.03e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—BLVRB—esophageal cancer	8.64e-06	5.02e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC52A3—esophageal cancer	8.64e-06	5.02e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FBXW7—esophageal cancer	8.6e-06	5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH2—esophageal cancer	8.59e-06	5e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—NOS3—esophageal cancer	8.56e-06	4.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—EGFR—esophageal cancer	8.42e-06	4.9e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ALDOB—esophageal cancer	8.41e-06	4.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTT1—esophageal cancer	8.4e-06	4.89e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ADH1B—esophageal cancer	8.38e-06	4.87e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EGFR—esophageal cancer	8.33e-06	4.85e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NOS3—esophageal cancer	8.31e-06	4.83e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP2A6—esophageal cancer	8.31e-06	4.83e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ADH1B—esophageal cancer	8.3e-06	4.83e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.27e-06	4.81e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NOS2—esophageal cancer	8.19e-06	4.76e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—PIK3CA—esophageal cancer	8.19e-06	4.76e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—NOTCH1—esophageal cancer	8.18e-06	4.76e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GAPDH—esophageal cancer	8.09e-06	4.71e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PIK3CA—esophageal cancer	8.07e-06	4.69e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—EP300—esophageal cancer	8.06e-06	4.69e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CRABP1—esophageal cancer	8.02e-06	4.66e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TYMP—esophageal cancer	8.01e-06	4.65e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TYMP—esophageal cancer	7.94e-06	4.61e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—esophageal cancer	7.92e-06	4.61e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—PIK3CA—esophageal cancer	7.92e-06	4.6e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ENO1—esophageal cancer	7.87e-06	4.58e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTGS1—esophageal cancer	7.87e-06	4.58e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MYC—esophageal cancer	7.87e-06	4.57e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—esophageal cancer	7.83e-06	4.55e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP26A1—esophageal cancer	7.79e-06	4.53e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—ERBB2—esophageal cancer	7.77e-06	4.52e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PSME2—esophageal cancer	7.76e-06	4.51e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PSME1—esophageal cancer	7.76e-06	4.51e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—EP300—esophageal cancer	7.73e-06	4.49e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP26A1—esophageal cancer	7.72e-06	4.49e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EGFR—esophageal cancer	7.69e-06	4.47e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GNG7—esophageal cancer	7.63e-06	4.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFBR2—esophageal cancer	7.62e-06	4.43e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALOX15—esophageal cancer	7.59e-06	4.41e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALOX15—esophageal cancer	7.52e-06	4.37e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CASP8—esophageal cancer	7.49e-06	4.36e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PIK3CA—esophageal cancer	7.47e-06	4.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CREBBP—esophageal cancer	7.46e-06	4.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EGFR—esophageal cancer	7.44e-06	4.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—CREBBP—esophageal cancer	7.42e-06	4.31e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—CREBBP—esophageal cancer	7.35e-06	4.28e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC10A2—esophageal cancer	7.35e-06	4.27e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CA1—esophageal cancer	7.35e-06	4.27e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTO1—esophageal cancer	7.24e-06	4.21e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TPI1—esophageal cancer	7.24e-06	4.21e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PIK3CA—esophageal cancer	7.23e-06	4.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SMAD4—esophageal cancer	7.22e-06	4.2e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	7.19e-06	4.18e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TPI1—esophageal cancer	7.18e-06	4.17e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTO1—esophageal cancer	7.18e-06	4.17e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—PIK3CA—esophageal cancer	7.17e-06	4.17e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ALDH2—esophageal cancer	7.15e-06	4.16e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFBR2—esophageal cancer	6.96e-06	4.04e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALDOB—esophageal cancer	6.94e-06	4.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—esophageal cancer	6.93e-06	4.03e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALDOB—esophageal cancer	6.88e-06	4e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCND1—esophageal cancer	6.87e-06	3.99e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTT1—esophageal cancer	6.8e-06	3.95e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP2A6—esophageal cancer	6.72e-06	3.91e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CA2—esophageal cancer	6.72e-06	3.91e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP1B1—esophageal cancer	6.7e-06	3.89e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.69e-06	3.89e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GAPDH—esophageal cancer	6.68e-06	3.89e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—esophageal cancer	6.68e-06	3.88e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CDKN1A—esophageal cancer	6.64e-06	3.86e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GAPDH—esophageal cancer	6.62e-06	3.85e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CRABP1—esophageal cancer	6.62e-06	3.85e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SMAD4—esophageal cancer	6.58e-06	3.83e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NOS3—esophageal cancer	6.58e-06	3.83e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CRABP1—esophageal cancer	6.56e-06	3.82e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—EP300—esophageal cancer	6.51e-06	3.79e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—esophageal cancer	6.45e-06	3.75e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—BCL2—esophageal cancer	6.43e-06	3.74e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ENO1—esophageal cancer	6.37e-06	3.7e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS1—esophageal cancer	6.37e-06	3.7e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.37e-06	3.7e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EP300—esophageal cancer	6.32e-06	3.68e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GNG7—esophageal cancer	6.3e-06	3.66e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP19A1—esophageal cancer	6.3e-06	3.66e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PSME1—esophageal cancer	6.28e-06	3.65e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PSME2—esophageal cancer	6.28e-06	3.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ERBB2—esophageal cancer	6.25e-06	3.63e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ADH7—esophageal cancer	6.25e-06	3.63e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PLCE1—esophageal cancer	6.25e-06	3.63e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GNG7—esophageal cancer	6.24e-06	3.63e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—esophageal cancer	5.96e-06	3.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HIF1A—esophageal cancer	5.91e-06	3.43e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALDH2—esophageal cancer	5.9e-06	3.43e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALDH2—esophageal cancer	5.85e-06	3.4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—HMOX1—esophageal cancer	5.74e-06	3.34e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—esophageal cancer	5.71e-06	3.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KDR—esophageal cancer	5.65e-06	3.28e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.64e-06	3.28e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTT1—esophageal cancer	5.61e-06	3.26e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTT1—esophageal cancer	5.57e-06	3.24e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	5.55e-06	3.23e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ABCB1—esophageal cancer	5.51e-06	3.21e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—esophageal cancer	5.51e-06	3.2e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP2A6—esophageal cancer	5.5e-06	3.2e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.48e-06	3.19e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.48e-06	3.19e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ADH1B—esophageal cancer	5.48e-06	3.18e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP1B1—esophageal cancer	5.42e-06	3.15e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EGFR—esophageal cancer	5.39e-06	3.13e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HIF1A—esophageal cancer	5.39e-06	3.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1A—esophageal cancer	5.34e-06	3.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH1—esophageal cancer	5.32e-06	3.09e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ENO1—esophageal cancer	5.26e-06	3.06e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS1—esophageal cancer	5.26e-06	3.06e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TYMP—esophageal cancer	5.23e-06	3.04e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS1—esophageal cancer	5.21e-06	3.03e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ENO1—esophageal cancer	5.21e-06	3.03e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PSME2—esophageal cancer	5.18e-06	3.01e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PSME1—esophageal cancer	5.18e-06	3.01e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PSME2—esophageal cancer	5.14e-06	2.99e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PSME1—esophageal cancer	5.14e-06	2.99e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP19A1—esophageal cancer	5.09e-06	2.96e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	5.09e-06	2.96e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EP300—esophageal cancer	5.08e-06	2.95e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—EP300—esophageal cancer	5.01e-06	2.91e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.96e-06	2.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOS2—esophageal cancer	4.9e-06	2.85e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOTCH1—esophageal cancer	4.85e-06	2.82e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CREBBP—esophageal cancer	4.82e-06	2.8e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—esophageal cancer	4.82e-06	2.8e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTO1—esophageal cancer	4.73e-06	2.75e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TPI1—esophageal cancer	4.73e-06	2.75e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—esophageal cancer	4.68e-06	2.72e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—HMOX1—esophageal cancer	4.65e-06	2.7e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.56e-06	2.65e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALDOB—esophageal cancer	4.54e-06	2.64e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—esophageal cancer	4.52e-06	2.63e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.49e-06	2.61e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	4.47e-06	2.6e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ABCB1—esophageal cancer	4.46e-06	2.59e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	4.43e-06	2.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—esophageal cancer	4.4e-06	2.56e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CREBBP—esophageal cancer	4.4e-06	2.56e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GAPDH—esophageal cancer	4.37e-06	2.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGFR—esophageal cancer	4.33e-06	2.52e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CRABP1—esophageal cancer	4.33e-06	2.52e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOS3—esophageal cancer	4.32e-06	2.51e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	4.21e-06	2.45e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	4.17e-06	2.42e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.17e-06	2.42e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GNG7—esophageal cancer	4.12e-06	2.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ERBB2—esophageal cancer	4.04e-06	2.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOS3—esophageal cancer	3.94e-06	2.29e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.86e-06	2.24e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HMOX1—esophageal cancer	3.84e-06	2.23e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HMOX1—esophageal cancer	3.8e-06	2.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—esophageal cancer	3.76e-06	2.19e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.73e-06	2.17e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—esophageal cancer	3.7e-06	2.15e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CREBBP—esophageal cancer	3.69e-06	2.14e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERBB2—esophageal cancer	3.69e-06	2.14e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.68e-06	2.14e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.67e-06	2.13e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ABCB1—esophageal cancer	3.65e-06	2.12e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.63e-06	2.11e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—esophageal cancer	3.58e-06	2.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—esophageal cancer	3.57e-06	2.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1A—esophageal cancer	3.45e-06	2.01e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ENO1—esophageal cancer	3.44e-06	2e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.44e-06	2e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PSME2—esophageal cancer	3.39e-06	1.97e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PSME1—esophageal cancer	3.39e-06	1.97e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.37e-06	1.96e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—NOS3—esophageal cancer	3.3e-06	1.92e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EP300—esophageal cancer	3.29e-06	1.91e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1A—esophageal cancer	3.15e-06	1.83e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EP300—esophageal cancer	3e-06	1.74e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CREBBP—esophageal cancer	2.98e-06	1.73e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.92e-06	1.7e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—esophageal cancer	2.86e-06	1.66e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGFR—esophageal cancer	2.8e-06	1.63e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.76e-06	1.61e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.75e-06	1.6e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NOS3—esophageal cancer	2.67e-06	1.55e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—esophageal cancer	2.61e-06	1.52e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGFR—esophageal cancer	2.55e-06	1.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—EP300—esophageal cancer	2.51e-06	1.46e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.51e-06	1.46e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.46e-06	1.43e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—esophageal cancer	2.44e-06	1.42e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.44e-06	1.42e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—esophageal cancer	2.43e-06	1.41e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.41e-06	1.4e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—esophageal cancer	2.35e-06	1.37e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—esophageal cancer	2.22e-06	1.29e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NOS3—esophageal cancer	2.2e-06	1.28e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NOS3—esophageal cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—EP300—esophageal cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.02e-06	1.17e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—esophageal cancer	2e-06	1.16e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—esophageal cancer	1.86e-06	1.08e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—EP300—esophageal cancer	1.68e-06	9.75e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—EP300—esophageal cancer	1.66e-06	9.66e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.61e-06	9.36e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—esophageal cancer	1.5e-06	8.73e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NOS3—esophageal cancer	1.44e-06	8.38e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.32e-06	7.66e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.24e-06	7.21e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.23e-06	7.15e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—EP300—esophageal cancer	1.1e-06	6.37e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	8.11e-07	4.71e-06	CbGpPWpGaD
